ADAM17 mediates OSCC development in an orthotopic murine model

Area of Science:

• Molecular Biology
• Cancer Research
• Proteomics

Background:

• ADAM17 is a key sheddase involved in releasing signaling molecules like EGFR ligands.
• The interaction between ADAM17 and EGFR is a potential therapeutic target in oral squamous cell carcinoma (OSCC).
• The precise role of ADAM17 in OSCC development remains unclear.

Purpose of the Study:

• To investigate the effect of ADAM17 overexpression on OSCC cell behavior in vitro.
• To evaluate the impact of ADAM17 overexpression on tumor growth and molecular characteristics in vivo.
• To elucidate the role of ADAM17 in OSCC development and its potential as a therapeutic target.

Main Methods:

• In vitro assessment of cell migration, viability, adhesion, and proliferation with ADAM17 overexpression.
• In vivo studies using immunodeficient mice injected with SCC-9 cells overexpressing ADAM17.
• MS-based proteomics to analyze protein expression in tumor tissues and identify regulated pathways.

Main Results:

• ADAM17 overexpression significantly increased cell viability, migration, adhesion, and proliferation in vitro.
• In vivo, ADAM17 overexpression led to larger tumor size, increased proliferative activity, and higher collagenase activity.
• Proteomic analysis identified differentially expressed proteins and implicated the Erk pathway in ADAM17-mediated OSCC progression.

Conclusions:

• ADAM17 plays a significant role in oral cancer development.
• ADAM17 represents a promising therapeutic target for OSCC.
• These findings support the development of novel strategies for OSCC treatment.